Filing Details
- Accession Number:
- 0000950170-25-074325
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-05-19 16:05:28
- Reporting Period:
- 2025-05-15
- Filing Date:
- 2025-05-19
- Accepted Time:
- 2025-05-19 16:05:28
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1609809 | Seres Therapeutics Inc. | MCRB | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1435744 | Thomas Desrosier | C/O Seres Therapeutics, Inc. 101 Cambridge Park Drive Cambridge MA 02140 | Chief Legal Officer And Evp | No | No | No | No |
Transaction Summary
| Sold: | 79 shares | Avg. Price: $7.28 | Total Value: $575.12 |
| Number of Shares After Transactions: | 7,287 shares | ||
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2025-05-15 | 133 | $0.00 | 7,255 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2025-05-15 | 111 | $0.00 | 7,366 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2025-05-15 | 79 | $7.28 | 7,287 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Restricted Stock Units | Disposition | 2025-05-15 | 133 | $0.00 | 133 | $0.00 |
| Common Stock | Restricted Stock Units | Disposition | 2025-05-15 | 111 | $0.00 | 111 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 929 | No | 4 | M | Direct | ||
| 1,224 | No | 4 | M | Direct |
Footnotes
- Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
- Reflects a 1-for-20 reverse stock split effected on April 21, 2025.
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
- The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
- The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
Billionaire Hedge Funds
